Dan Iosifescu

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi 31P-magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: toward a bioenergetic mechanism in depression?
    Dan V Iosifescu
    Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital, Boston 02114, USA
    Harv Rev Psychiatry 11:51-63. 2003
  2. ncbi Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study
    Dan V Iosifescu
    The Bipolar Clinic and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    CNS Neurosci Ther 15:309-19. 2009
  3. ncbi Frontal EEG predictors of treatment outcome in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, United States
    Eur Neuropsychopharmacol 19:772-7. 2009
  4. ncbi Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder
    D V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    Acta Psychiatr Scand 117:271-6. 2008
  5. ncbi Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Biol Psychiatry 63:1127-34. 2008
  6. ncbi Treating depression in the medically ill
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, 50 Staniford Street, Suite 401, Boston, MA 02114, USA
    Psychiatr Clin North Am 30:77-90. 2007
  7. ncbi Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Psychosom Med 67:703-6. 2005
  8. ncbi An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 66:1038-42. 2005
  9. ncbi Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment
    Dan V Iosifescu
    Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Psychosomatics 45:419-25. 2004
  10. ncbi Impact of medical comorbid disease on antidepressant treatment of major depressive disorder
    Dan V Iosifescu
    Massachusetts General Hospital, 50 Staniford Street, Suite 401, Boston, MA 02114, USA
    Curr Psychiatry Rep 6:193-201. 2004

Research Grants

  1. Depression and Brain Metabolism
    Dan Iosifescu; Fiscal Year: 2007
  2. Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder
    Dan Iosifescu; Fiscal Year: 2009

Detail Information

Publications12

  1. ncbi 31P-magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: toward a bioenergetic mechanism in depression?
    Dan V Iosifescu
    Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital, Boston 02114, USA
    Harv Rev Psychiatry 11:51-63. 2003
    ..g., with thyroid hormones) is a valid therapeutic strategy for improving the symptoms of MDD. We discuss our hypothesis in the context of other current theories on the mechanism of thyroid hormones in MDD...
  2. ncbi Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study
    Dan V Iosifescu
    The Bipolar Clinic and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    CNS Neurosci Ther 15:309-19. 2009
    ..Many subjects with bipolar disorder experience significant cognitive dysfunction, even when euthymic, but few studies assess biological correlates of or treatment strategies for cognitive dysfunction...
  3. ncbi Frontal EEG predictors of treatment outcome in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, United States
    Eur Neuropsychopharmacol 19:772-7. 2009
    ..To investigate the role of frontal EEG as predictor of clinical response to SSRIs or venlafaxine in major depressive disorder (MDD)...
  4. ncbi Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder
    D V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    Acta Psychiatr Scand 117:271-6. 2008
    ..We investigated frontal quantitative EEG (QEEG) as predictor of changes in suicidal ideation (SI) during SSRI treatment in major depressive disorder (MDD)...
  5. ncbi Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Biol Psychiatry 63:1127-34. 2008
    ..We assessed whether changes in brain bioenergetics measured with phosphorus magnetic resonance spectroscopy ((31)P MRS) correlate with treatment outcome during augmentation treatment with triiodothyronine (T3) in MDD...
  6. ncbi Treating depression in the medically ill
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, 50 Staniford Street, Suite 401, Boston, MA 02114, USA
    Psychiatr Clin North Am 30:77-90. 2007
    ....
  7. ncbi Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Psychosom Med 67:703-6. 2005
    ..In this study, we measured the impact of cardiovascular risk factors on the outcome of antidepressant treatment in major depressive disorder (MDD)...
  8. ncbi An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 66:1038-42. 2005
    ..In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment...
  9. ncbi Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment
    Dan V Iosifescu
    Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Psychosomatics 45:419-25. 2004
    ..Greater medical comorbidity was also associated with higher increases in self-reported symptoms of depression, anxiety, and anger during the follow-up...
  10. ncbi Impact of medical comorbid disease on antidepressant treatment of major depressive disorder
    Dan V Iosifescu
    Massachusetts General Hospital, 50 Staniford Street, Suite 401, Boston, MA 02114, USA
    Curr Psychiatry Rep 6:193-201. 2004
    ..In addition, the authors will review hypotheses on the mechanism of the interaction between medical illness and clinical response in MDD. The paper will conclude that medical comorbidity is a predictor of treatment resistance in MDD...
  11. ncbi The impact of medical comorbidity on acute treatment in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Psychiatry Department, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Am J Psychiatry 160:2122-7. 2003
    ..The authors investigated the impact of medical comorbidity on the acute phase of antidepressant treatment in subjects with major depressive disorder...
  12. ncbi A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study)
    Maurizio Fava
    Clinical Trials and Network Institute CTNI, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychother Psychosom 81:87-97. 2012
    ..We assessed the efficacy of low-dose aripiprazole added to antidepressant therapy (ADT) in major depressive disorder (MDD) patients with inadequate response to prior ADT...

Research Grants3

  1. Depression and Brain Metabolism
    Dan Iosifescu; Fiscal Year: 2007
    ..The development of a larger scale R01 project investigating the role of brain energy metabolism in a population of treatment-resistant subjects with MDD will be started during the last two years of the award period. ..
  2. Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder
    Dan Iosifescu; Fiscal Year: 2009
    ....